Compare Arm Holdings plc (ARM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arm Holdings plc vs TG Therapeutics Inc — how do they compare? Arm Holdings plc trades at $273.1 (market cap $287.22B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Arm Holdings plc is far larger — about 37.6× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Arm Holdings plc nearer its low. Which is the better fit depends on your goals.
| ARM | TGTX | |
|---|---|---|
Market Cap | $287.22B | $7.64B |
Sector | Technology | Health |
52-Week High | $439.46 | $59.06 |
52-Week Low | $104.55 | $26.94 |
Enterprise Value | $283.79B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARM stock trades at $271.87, up 1.5% in the last 24 hours, with a bullish technical signal and strong quarterly earnings beats. The company reported robust revenue growth, reaching $4.01 billion in 2025, with a net income margin of 20.25%. Recent news highlights AI-driven optimism, though valuation metrics like a P/E of 274.42 indicate premium pricing.
Outlook is positive with analyst consensus favoring a buy rating (70.37%) and a $329.80 price target, but risks include high valuation sensitivity and competitive pressures in the smartphone market. Earnings growth from AI and data center demand presents opportunity, yet investors must weigh stretched multiples against execution risks.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
